Protagonist Therapeutics, Inc Available-for-sale Securities, Gross Realized Gain (Loss)
Protagonist Therapeutics, Inc (PTGX) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $0 for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2017-11-07
- Protagonist Therapeutics, Inc available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-09-30 was $0.00.
- Protagonist Therapeutics, Inc available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-06-30 was $0.00.
- Protagonist Therapeutics, Inc available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-03-31 was $0.00.
- Protagonist Therapeutics, Inc available-for-sale securities, gross realized gain (loss) for the quarter ending 2016-12-31 was $0.00.
- Protagonist Therapeutics, Inc available-for-sale securities, gross realized gain (loss) for fiscal 2015 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | $0.00 derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $0.00 10-Q · filed 2017-08-08 | $0.00 derived: sum of 3 quarters · filed 2017-11-07 | $0.00 derived: sum of 4 quarters · filed 2017-11-07 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $0.00 derived: sum of 3 quarters · filed 2017-11-07 | |
| 2016-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | $0.00 10-Q · filed 2016-09-15 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |